Literature DB >> 11474495

Ionizing radiation as a response-enhancing agent for CD95-mediated apoptosis.

M A Sheard1.   

Abstract

CD95 (Fas/APO-1) is a death receptor on the surface of a wide variety of cell types. In most cells examined, ionizing radiation acts as a response-enhancing agent for CD95-mediated cell death. Although DNA-damaging radiation appears to modulate CD95-mediated signals through multiple mechanisms, the only well-characterized mechanism is activation of the tumor-suppressor protein p53, which transcriptionally regulates the expression of CD95 on various cell types. The ligand for CD95 is expressed by activated lymphocytes and natural-killer cells, which produce factors that sensitize cells resistant to CD95-mediated cell death. Ligation of CD95 on irradiated tumor cells might be achievable using emerging modalities that reactivate the stalled anti-tumor immune response. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474495     DOI: 10.1002/ijc.1020

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Transcriptional response of lymphoblastoid cells to ionizing radiation.

Authors:  Kuang-Yu Jen; Vivian G Cheung
Journal:  Genome Res       Date:  2003-08-12       Impact factor: 9.043

Review 2.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 3.  Combining radiotherapy and immunotherapy: a revived partnership.

Authors:  Sandra Demaria; Nina Bhardwaj; William H McBride; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

4.  CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

Authors:  Frank Dicker; Arnon P Kater; Carlos E Prada; Tetsuya Fukuda; Januario E Castro; Guizhen Sun; Jean Y Wang; Thomas J Kipps
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

5.  Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinoma.

Authors:  Jeffrey S Moyer; Ji Li; Shuang Wei; Seagal Teitz-Tennenbaum; Alfred E Chang
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

6.  The convergence of radiation and immunogenic cell death signaling pathways.

Authors:  Encouse B Golden; Ilenia Pellicciotta; Sandra Demaria; Mary H Barcellos-Hoff; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-08-07       Impact factor: 6.244

Review 7.  Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored.

Authors:  Luis de la Cruz-Merino; Ana Illescas-Vacas; Ana Grueso-López; Antonio Barco-Sánchez; Carlos Míguez-Sánchez
Journal:  Front Immunol       Date:  2014-03-14       Impact factor: 7.561

Review 8.  Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization.

Authors:  Patrick Maier; Linda Hartmann; Frederik Wenz; Carsten Herskind
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

9.  Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.

Authors:  Fumito Kuranishi; Tadao Ohno
Journal:  World J Surg Oncol       Date:  2013-06-04       Impact factor: 2.754

10.  1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells.

Authors:  N Dunlap; G G Schwartz; D Eads; S D Cramer; A B Sherk; V John; C Koumenis
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.